Kathmandu. American pharma company Moderna's share price has skyrocketed. The company's share price has increased due to the news that the personalized mRNA cancer vaccine developed by the company, when used in combination with the immunotherapy drug Keytruda, has shown encouraging results in patients with deadly skin cancer melanoma.Moderna and Merck, the company that makes Keytruda, said on Wednesday that the treatment had met its primary goal in the latest phase of clinical trials.The impact of this news was immediately visible in the market. Moderna's share price saw a significant increase after the positive results of the trial were made...